Walleye Capital
BXRX

Walleye Capital’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

Walleye Capital’s Portfolio BXRX Stock Details BXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4,882
Closed -$165K – 3778
2022
Q2 		$165K Buy
+4,882
New +$228K ﹤0.01% 1589

Other funds holding BXRX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Walleye Capital's BXRX Position: Q3 2022 in Review

Walleye Capital sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q3 2022, closing a stake of 4,882 shares — an estimated $165K sold.

Walleye Capital first reported a position in BXRX in Q2 2022 and held it in 1 quarter. The position peaked at $165K in Q2 2022. 20 funds tracked by Wall St. Rank hold BXRX as of Q3 2022.

  • Walleye Capital reported no remaining Baudax Bio, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Walleye Capital sold 4,882 Baudax Bio, Inc. Common Stock shares in Q3 2022, an estimated $165K.
  • Walleye Capital first reported a position in Baudax Bio, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Walleye Capital's Baudax Bio, Inc. Common Stock position peaked at $165K in Q2 2022.
  • 20 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q3 2022.

Based on Walleye Capital's 13F filing for Q3 2022, filed 14 Nov 2022.